117 related articles for article (PubMed ID: 36007556)
41. Factorial designed 5-fluorouracil-loaded microsponges and calcium pectinate beads plugged in hydroxypropyl methylcellulose capsules for colorectal cancer.
Gupta A; Tiwari G; Tiwari R; Srivastava R
Int J Pharm Investig; 2015; 5(4):234-46. PubMed ID: 26682194
[TBL] [Abstract][Full Text] [Related]
42. Development and Evaluation of pH-Dependent Micro Beads for Colon Targeting.
Khan MS; Sridhar BK; Srinatha A
Indian J Pharm Sci; 2010 Jan; 72(1):18-23. PubMed ID: 20582185
[TBL] [Abstract][Full Text] [Related]
43. Alpha-mangostin and resveratrol, dual-drugs-loaded mucoadhesive thiolated chitosan-based nanoparticles for synergistic activity against colon cancer cells.
Samprasit W; Opanasopit P; Chamsai B
J Biomed Mater Res B Appl Biomater; 2022 Jun; 110(6):1221-1233. PubMed ID: 34919783
[TBL] [Abstract][Full Text] [Related]
44. Fluvastatin attenuated the effect of expression of β1 integrin in PAN-treated podocytes by inhibiting reactive oxygen species.
Liu J; Zhang B; Chai Y; Xu Y; Xing C; Wang X
Mol Cell Biochem; 2015 Jan; 398(1-2):207-15. PubMed ID: 25240415
[TBL] [Abstract][Full Text] [Related]
45. Electrosprayed chitosan-coated alginate-pectin beads as potential system for colon-targeted delivery of ellagic acid.
Karakas CY; Ordu HR; Bozkurt F; Karadag A
J Sci Food Agric; 2022 Feb; 102(3):965-975. PubMed ID: 34302363
[TBL] [Abstract][Full Text] [Related]
46. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad U; Abbas T; Dutta A
Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065
[TBL] [Abstract][Full Text] [Related]
47. Novel thymoquinone lipidic core nanocapsules with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors.
Ramzy L; Metwally AA; Nasr M; Awad GAS
Sci Rep; 2020 Jul; 10(1):10987. PubMed ID: 32620860
[TBL] [Abstract][Full Text] [Related]
48. Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
Zhang T; Bai R; Wang Q; Wang K; Li X; Liu K; Ryu J; Wang T; Chang X; Ma W; Bode AM; Xia Q; Song Y; Dong Z
Cancer Prev Res (Phila); 2019 Dec; 12(12):837-848. PubMed ID: 31554629
[TBL] [Abstract][Full Text] [Related]
49. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
50. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
51. Triggering of cancer cell cycle arrest by a novel scorpion venom-derived peptide-Gonearrestide.
Li B; Lyu P; Xi X; Ge L; Mahadevappa R; Shaw C; Kwok HF
J Cell Mol Med; 2018 Sep; 22(9):4460-4473. PubMed ID: 29993185
[TBL] [Abstract][Full Text] [Related]
52. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
53. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.
Ali N; Allam H; Bader T; May R; Basalingappa KM; Berry WL; Chandrakesan P; Qu D; Weygant N; Bronze MS; Umar S; Janknecht R; Sureban SM; Huycke M; Houchen CW
PLoS One; 2013; 8(11):e80304. PubMed ID: 24260365
[TBL] [Abstract][Full Text] [Related]
54. Cross-linked Alginate Beads of Montelukast Sodium Coated with Eudragit for Chronotherapy: Statistical Optimization,
Ranjan OP; Kumar N; Dave V
Curr Drug Deliv; 2022; 19(10):1047-1060. PubMed ID: 35189803
[TBL] [Abstract][Full Text] [Related]
55. Chitosan Coated Microparticles Enhance Simvastatin Colon Targeting and Pro-Apoptotic Activity.
Alhakamy NA; Fahmy UA; Ahmed OAA; Caruso G; Caraci F; Asfour HZ; Bakhrebah MA; N Alomary M; Abdulaal WH; Okbazghi SZ; Abdel-Naim AB; Eid BG; Aldawsari HM; Kurakula M; Mohamed AI
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32344610
[TBL] [Abstract][Full Text] [Related]
56. Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach.
Rajpoot K; Jain SK
Int J Biol Macromol; 2020 May; 151():830-844. PubMed ID: 32061847
[TBL] [Abstract][Full Text] [Related]
57. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer.
Negi LM; Jaggi M; Joshi V; Ronodip K; Talegaonkar S
Int J Biol Macromol; 2015 Feb; 73():222-35. PubMed ID: 25478964
[TBL] [Abstract][Full Text] [Related]
58. Mevastatin in colon cancer by spectroscopic and microscopic methods - Raman imaging and AFM studies.
Beton K; Wysocki P; Brozek-Pluska B
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Apr; 270():120726. PubMed ID: 34979441
[TBL] [Abstract][Full Text] [Related]
59. Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability.
Faris TM; Harisa GI; Alanazi FK; Samy AM; Nasr FA
Saudi Pharm J; 2020 Dec; 28(12):1851-1867. PubMed ID: 33424274
[TBL] [Abstract][Full Text] [Related]
60. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
Mascaró C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
